Surging Ahead with the Next Wave of Precision Immuno-Oncology to Unleash the Power of T-cell Immunity
Time: 9:25 am
day: Conference Day One
Details:
- TCR-targeted therapies utilize engineered T-cell receptors to precisely recognize a variety of cancer antigens presented on cell surface via MHC molecules, allowing for targeted attack against a broad range of cancers at their core
- These therapies offer increased specificity by targeting intracellular antigens, potentially addressing tumor heterogeneity and providing a more comprehensive approach compared to surface antigen-targeting therapies like CAR-T or ADC
- Ongoing research aims to further improve TCR-based immunotherapy’s efficacy, reduce adverse effects, and broaden applicability across different cancer types, ushering in the next wave of precision immunotherapy
